Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Patent Option and Technology License Agreement - Additional Information (Detail)

Patent Option and Technology License Agreement - Additional Information (Detail)					3 Months Ended		6 Months Ended
	Feb. 04, 2022 USD ($)	Feb. 23, 2021 USD ($)	Dec. 01, 2020 USD ($)	Jun. 30, 2020 USD ($)	May 31, 2022 USD ($) ft²	May 31, 2021 USD ($)	May 31, 2022 USD ($) ft²	May 31, 2021 USD ($)	Feb. 28, 2022	Feb. 28, 2021 USD ($) shares
Patent Option And Technology License Agreement [Line Items]
Long-term line of credit				$ 350,000
Line of credit facility			$ 150,000	$ 150,000
Revenue					$ 7,633,217	$ 7,205,195	$ 14,891,748	$ 14,065,812
Duke University [Member]
Patent Option And Technology License Agreement [Line Items]
License fee payable			$ 12,000,000
Milestone payments first phase III clinical trial	$ 2,000,000	$ 2,000,000
Capitalized costs to obtain agreement										$ 15,372,382
Present value of license fee										12,000,000
Number of common stock value transferred										$ 3,585,172
Number of common stock shares transferred \| shares										409,734
Capitalized costs amortization period									16 years
Amortization expense					$ 240,194	$ 240,193	$ 480,387	$ 240,193
Duke University [Member] \| 5.0% upon Execution of the Agreement [Member] \| Fully Diluted Equity Ownership
Patent Option And Technology License Agreement [Line Items]
Common Stock Equal Full Diluted Equity Ownership Outstanding Percentage		5.00%
Duke University [Member] \| 2.5% Market Cap [Member] \| Fully Diluted Equity Ownership
Patent Option And Technology License Agreement [Line Items]
Common Stock Equal Full Diluted Equity Ownership Outstanding Percentage		2.50%
Duke University [Member] \| Minimum [Member]
Patent Option And Technology License Agreement [Line Items]
Royalties Percentage Portion of Net Sales		7.00%
Duke University [Member] \| Minimum [Member] \| 2.5% Market Cap Triggers with 18 Months [Member] \| Fully Diluted Equity Ownership
Patent Option And Technology License Agreement [Line Items]
Average Closing Market Capital		$ 300,000,000
Duke University [Member] \| Minimum [Member] \| 2.5% Market Cap Triggers with 24 Months [Member] \| Fully Diluted Equity Ownership
Patent Option And Technology License Agreement [Line Items]
Average Closing Market Capital		$ 500,000,000
Duke University [Member] \| Maximum [Member]
Patent Option And Technology License Agreement [Line Items]
Royalties Percentage Portion of Net Sales		12.50%
Duke University [Member] \| Within Fourteen (14) days of February 23, 2021
Patent Option And Technology License Agreement [Line Items]
License fee payable		$ 10,000,000
Duke University [Member] \| Second Anniversary [Member]
Patent Option And Technology License Agreement [Line Items]
Minimum Annual Royalties Due Year Two		500,000
Minimum Annual Royalties Due Year Three		1,000,000
Minimum Annual Royalties Due Year Four		2,500,000
Minimum Annual Royalties Due Year Five		5,000,000
Minimum Annual Royalties Due After Year Five		$ 5,000,000
Duke University [Member] \| Third Anniversary [Member]
Patent Option And Technology License Agreement [Line Items]
Minimum Annual Royalties Due Year Three	500,000
Minimum Annual Royalties Due Year Four	1,000,000
Minimum Annual Royalties Due Year Five	2,500,000
Minimum Annual Royalties Due Year Six	5,000,000
Minimum Annual Royalties Due After Year Six	$ 5,000,000
Duke University [Member] \| Licensed Product and Licensed Process [Member]
Patent Option And Technology License Agreement [Line Items]
Area of medical condominium building \| ft²					56,000		56,000
Royalties Term							15 years
Duke University [Member] \| Licensed Product and Licensed Process [Member] \| 2.5% Upon Cumulative Net Sales [Member] \| Fully Diluted Equity Ownership
Patent Option And Technology License Agreement [Line Items]
Common Stock Equal Full Diluted Equity Ownership Outstanding Percentage		2.50%
Revenue		$ 10,000,000
Duke University [Member] \| Licensed Product and Licensed Process [Member] \| 2.5% Upon Cumulative Net Sales [Member] \| Fully Diluted Equity Ownership
Patent Option And Technology License Agreement [Line Items]
Common Stock Equal Full Diluted Equity Ownership Outstanding Percentage		2.50%
Revenue		$ 75,000,000